Table 4

Subgroup analysis of PhenoAgeAccel and lung function

FEV1, mL
β (95% CI)
FVC, mL
β (95% CI)
FEV1 %, predicted
β (95% CI)
FVC %, predicted
β (95% CI)
PhenoAgeAccel, (continuous)
COPD
No−6.86 (−9.25 to −4.47)−9.10 (−12.3 to −5.94)−0.14 (−0.21 to −0.06)−0.14 (−0.22 to −0.06)
Yes−13.1 (−18.8 to −7.38)−17.1 (−24.9 to −9.35)−0.40 (−0.60 to −0.20)−0.38 (−0.57 to −0.18)
P for interaction0.0210.0340.0230.051
Smoking index
<10, pack-years−9.17 (−11.4 to −6.98)−10.5 (−14.0 to −6.88)−0.23 (−0.30 to −0.17)−0.19 (−0.27 to −0.11)
10–20, pack-years−10.5 (−19.3 to −1.66)−10.4 (−21.4 to 0.61)−0.26 (−0.58 to 0.05)−0.18 (−0.49 to 0.13)
>20, pack-years−8.84 (−15.8 to −1.85)−10.7(−19.1 to −2.24)−0.20 (−0.44 to 0.03)−0.18 (−0.42 to 0.05)
P for interaction0.740.680.800.83
Age
<65 years−7.13 (−10.5 to 3.82)−7.47 (−12.0 to −2.94)−0.14 (−0.24 to −0.04)−0.09 (−0.19 to 0.02)
≥65 years−13.8 (−18.5 to −9.07)−16.0 (−21.8 to −10.2)−0.53 (−0.69 to −0.37)−0.44 (−0.59 to −0.28)
0.0270.045< 0.0010.005
Sex
Female−7.49 (−10.8 to 4.23)−8.05 (−12.3 to −3.77)−0.22 (−0.37 to −0.08)−0.16 (−0.30 to 0.01)
Male−10.8 (−14.9 to −6.78)−13.8 (−18.6 to −8.98)−0.26 (−0.35 to −0.17)−0.24 (−0.33 to −0.15)
P for interaction0.0840.0160.750.94
Race/ethnicity, n (%)
Non-Hispanic white−11.1 (−14.2 to −7.91)−12.9 (−17.5 to −8.27)−0.30 (−0.41 to −0.19)−0.26 (−0.38 to −0.14)
Mexican American−3.93 (−8.73 to 0.87)−4.59 (−10.4 to 1.17)−0.17 (−0.30 to −0.03)−0.15 (−0.27 to −0.03)
Non-Hispanic black−4.33 (−8.34 to −0.32)−2.94 (−6.75 to 0.88)−0.18 (−0.31 to −0.05)−0.11 (−0.22 to 0.00)
Other race−7.73 (−12.5 to −3.00)−8.40 (−14.9 to −1.92)−0.26 (−0.40 to −0.12)−0.21 (−0.33 to −0.08)
P for interaction0.0620.0570.0040.004
  • Adjusted for age, sex and race, body mass index, smoking index, education, cardiovascular disease, asthma, diabetes and hypertension.

  • Bold values signifies P for interaction < 0.05 proved that PhenoAgeAccel had an interaction in this subgroup.

  • A, A; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; PhenoAgeAccel, phenotypic age acceleration.